Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs MPLX LP — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while MPLX LP trades at $56.35 (market cap $58.11B). The key difference: MPLX LP is far larger — about 4.6× Halozyme Therapeutics Inc. Common Stock's market cap, and MPLX LP pays a 7.51% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HALO | MPLX | |
|---|---|---|
Market Cap | $12.58B | $58.11B |
Volume | 2,179,278 | 687,483 |
Sector | Health | Energy |
52-Week High | $115.22 | $60.51 |
52-Week Low | $61.63 | $47.80 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $14.49B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MPLX trades at $56.30, down 1.31% today, with a bearish technical signal and mixed earnings history including a recent Q2 2026 EPS miss. The company maintains strong profitability with a 40.45% net income margin and robust cash flow, supporting a $1.08 dividend. Analyst consensus is bullish with a $63.80 price target, though technical indicators show near-term resistance at $58.
The outlook for MPLX is positive due to its fee-based revenue model, high dividend yield, and analyst support, but risks include energy market volatility and recent earnings misses. Investors may find value in its cash flow stability, though caution is warranted given bearish technical trends and macroeconomic pressures on the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
